Skip to main content
SpringerLink
Log in

Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease

  • Living reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 198 Accesses

Abstract

Management of Parkinson’s disease is complex and involves several pharmacologic principles. It is essential to understand the peculiarities of each pharmacologic compound in terms of pharmacology and biochemistry. This is the precondition to perform a personalized therapy of Parkinson’s disease. Efficacy and safety of drugs is different in each patient. A treatment regimen needs to be adapted to the individual needs of each patient. This is essential to obtain maximum clinical benefit without exposing the patient to unacceptable risks. Combination regimes of multiple pharmacologic agents are common and potentially useful. Cautious, slow titration is essential to limit potential interactions and onset of adverse events. Symptoms often respond to monotherapy or to simple combinations of dopamine-substituting drugs in early stages of the disease. In more advanced stages, drugs are combined more and more on an individual basis. This chapter reviews essential modes of action of drugs such as anticholinergics, glutamate antagonists, levodopa and its complimenting approaches, monoamine oxidase inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Abercrombie ED, DeBoer P. Substantia nigra D1 receptors and stimulation of striatal cholinergic interneurons by dopamine: a proposed circuit mechanism. J Neurosci. 1997;17(21):8498–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Aquilonius SM, Nyholm D. Development of new levodopa treatment strategies in Parkinson’s disease-from bedside to bench to bedside. Ups J Med Sci. 2017;122(2):71–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bennett KA, Tehan B, Lebon G, Tate CG, Weir M, Marshall F, et al. Pharmacology and structure of isolated conformations of the adenosine A2A receptor define ligand efficacy. Mol Pharmacol. 2013;83(5):949–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, Chase TN. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol. 2005;196(2):422–9.

    Article  CAS  PubMed  Google Scholar 

  • Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR first study group. Eur Neurol. 1997;37(1):23–7.

    Article  CAS  PubMed  Google Scholar 

  • Calabresi P, Di FM, Ghiglieri V, Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov Disord. 2008;23(Suppl 3):S570–9.

    Article  PubMed  Google Scholar 

  • Cenci MA. Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci. 2007;30(5):236–43.

    Article  CAS  PubMed  Google Scholar 

  • Cenci MA, Konradi C. Maladaptive striatal plasticity in L-DOPA-induced dyskinesia. Prog Brain Res. 2010;183:209–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chen C, Cowles VE, Sweeney M, Stolyarov ID, Illarioshkin SN. Pharmacokinetics and pharmacodynamics of gastroretentive delivery of levodopa/carbidopa in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(2):67–72.

    Article  CAS  PubMed  Google Scholar 

  • Chen W, Wang H, Wei H, Gu S, Wei H. Istradefylline, an adenosine A(2)A receptor antagonist, for patients with Parkinson’s disease: a meta-analysis. J Neurol Sci. 2013;324(1–2):21–8.

    Article  CAS  PubMed  Google Scholar 

  • Ciobica A, Olteanu Z, Padurariu M, Hritcu L. The effects of pergolide on memory and oxidative stress in a rat model of Parkinson’s disease. J Physiol Biochem. 2012;68(1):59–69.

    Article  CAS  PubMed  Google Scholar 

  • Del DP, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, et al. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord. 2001;16(3):515–20.

    Article  Google Scholar 

  • Dorozynski P, Kulinowski P, Mendyk A, Jachowicz R. Gastroretentive drug delivery systems with L-dopa based on carrageenans and hydroxypropylmethylcellulose. Int J Pharm. 2011;404(1–2):169–75.

    Article  CAS  PubMed  Google Scholar 

  • Dupont E, Burgunder JM, Findley LJ, Olsson JE, Dorflinger E. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s disease study group II (TIPS II). Mov Disord. 1997;12(6):928–34.

    Article  CAS  PubMed  Google Scholar 

  • Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J. Dopamine autoreceptor function is lost in advanced Parkinson’s disease. Neurology. 1999;52(1):120–5.

    Article  CAS  PubMed  Google Scholar 

  • Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351(24):2498–508.

    Article  CAS  PubMed  Google Scholar 

  • Ferre S, Popoli P, Gimenez-Llort L, Rimondini R, Müller CE, Stromberg I, et al. Adenosine/dopamine interaction: implications for the treatment of Parkinson’s disease. Parkinsonism Relat Disord. 2001;7(3):235–41.

    Article  CAS  PubMed  Google Scholar 

  • Figee M, de KP, Klaassen S, Vulink N, Mantione M, van den MP, et al. Deep brain stimulation induces striatal dopamine release in obsessive-compulsive disorder. Biol Psychiatry. 2014;75(8):647–52.

    Article  CAS  PubMed  Google Scholar 

  • Fox SH. Non-dopaminergic treatments for motor control in Parkinson’s disease. Drugs. 2013;73(13):1405–15.

    Article  CAS  PubMed  Google Scholar 

  • Freitas ME, Ruiz-Lopez M, Fox SH. Novel levodopa formulations for Parkinson’s disease. CNS Drugs. 2016;30(11):1079–95.

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, Herranz BA, Vela L, Sanchez AP, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–4.

    Article  PubMed  Google Scholar 

  • Harati A, Müller T. Neuropsychological effects of deep brain stimulation for Parkinson’s disease. Surg Neurol Int. 2013;4(Suppl 6):S443–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096–9.

    Article  CAS  PubMed  Google Scholar 

  • Isacson D, Bingefors K, Kristiansen IS, Nyholm D. Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta Neurol Scand. 2008;118(6):379–86.

    Article  CAS  PubMed  Google Scholar 

  • Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs. 2000;59(6):1233–50.

    Article  CAS  PubMed  Google Scholar 

  • Kianirad Y, Simuni T. Novel approaches to optimization of levodopa therapy for Parkinson’s disease. Curr Neurol Neurosci Rep. 2016;16(4):34.

    Article  PubMed  CAS  Google Scholar 

  • Kleedorfer B, Lees AJ, Stern GM. Subcutaneous and sublingual levodopa methyl ester in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1991;54(4):373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Klostermann F, Jugel C, Bomelburg M, Marzinzik F, Ebersbach G, Müller T. Severe gastrointestinal complications in patients with levodopa/carbidopa intestinal gel infusion. Mov Disord. 2012a;27(13):1704–5.

    Article  PubMed  Google Scholar 

  • Klostermann F, Jugel C, Müller T, Marzinzik F. Malnutritional neuropathy under intestinal levodopa infusion. J Neural Transm (Vienna). 2012b;119(3):369–72.

    Article  CAS  Google Scholar 

  • Klostermann F, Bojarski C, Marzinzik F, Maier A, Schindlbeck KA, Ehlen F. Necessity of long-term alertness in levodopa-carbidopa intestinal gel infusion for PD patients. Mov Disord. 2017;32(2):300–1.

    Article  CAS  PubMed  Google Scholar 

  • Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol. 1989;166(3):589–90.

    Article  CAS  PubMed  Google Scholar 

  • Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206(4):297–300.

    Article  CAS  PubMed  Google Scholar 

  • Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Maki-Ikola O, et al. Lack of adverse interactions between concomitantly administered selegiline and citalopram. Clin Neuropharmacol. 1997;20(5):419–33.

    Article  CAS  PubMed  Google Scholar 

  • Lecht S, Haroutiunian S, Hoffman A, Lazarovici P. Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy. Ther Clin Risk Manag. 2007;3(3):467–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Lee YH, Kim KH, Yoon IK, Lee KE, Chun IK, Rhie JY, et al. Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems. Eur J Drug Metab Pharmacokinet. 2014;39(4):237–242.

    Article  PubMed  CAS  Google Scholar 

  • LeWitt PA, Huff FJ, Hauser RA, Chen D, Lissin D, Zomorodi K, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson’s disease. Mov Disord. 2014;29(1):75–82.

    Article  CAS  PubMed  Google Scholar 

  • Männisto PT, Tuomainen P, Tuominen RK. Different in vivo properties of three new inhibitors of catechol O-methyltransferase in the rat. Br J Pharmacol. 1992;105(3):569–74.

    Article  PubMed  PubMed Central  Google Scholar 

  • Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999;56(11):1383–6.

    Article  CAS  PubMed  Google Scholar 

  • Mittur A, Gupta S, Modi NB. Pharmacokinetics of Rytary((R)), an extended-release capsule formulation of carbidopa-levodopa. Clin Pharmacokinet. 2017;56(9):999–1014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Müller T. The impact of COMT-inhibition on gastrointestinal levodopa absorption in patients with Parkinson’s disease. Clin Med Insights: Ther. 2010;2:155–68.

    Google Scholar 

  • Müller T. Motor complications, levodopa metabolism and progression of Parkinson’s disease. Expert Opin Drug Metab Toxicol. 2011;7(7):847–55.

    Article  PubMed  CAS  Google Scholar 

  • Müller T. Drug therapy in patients with Parkinson’s disease. Transl Neurodegener. 2012;1(1):1–10.

    Article  CAS  Google Scholar 

  • Müller T. Current status of safinamide for the drug portfolio of Parkinson’s disease therapy. Expert Rev Neurother. 2013a;13(9):969–77.

    Article  PubMed  CAS  Google Scholar 

  • Müller T. Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson’s disease. Expert Rev Neurother. 2013b;13(6):707–18.

    Article  PubMed  CAS  Google Scholar 

  • Müller T. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Drugs. 2015;75(2):157–74.

    Article  PubMed  CAS  Google Scholar 

  • Müller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin Pharmacokinet. 2017;56(3):251–61.

    Article  PubMed  CAS  Google Scholar 

  • Müller T, Möhr JD. Recent clinical advances in pharmacotherapy for levodopa-induced dyskinesia. Drugs. 2019;79(13):1367–74.

    Article  PubMed  CAS  Google Scholar 

  • Müller T, Russ H. Levodopa, motor fluctuations and dyskinesia in Parkinson’s disease. Expert Opin Pharmacother. 2006;7(13):1715–30.

    Article  PubMed  Google Scholar 

  • Müller T, Kuhn W, Schulte T, Przuntek H. Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease. Neurosci Lett. 2003;339(1):25–8.

    Article  PubMed  Google Scholar 

  • Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, et al. Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients. Clin Neuropharmacol. 2006;29(2):61–7.

    Article  PubMed  Google Scholar 

  • Müller T, Kolf K, Ander L, Woitalla D, Muhlack S. Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease. Clin Neuropharmacol. 2008;31(3):134–40.

    Article  PubMed  CAS  Google Scholar 

  • Müller T, Tolosa E, Badea L, Asgharnejad M, Grieger F, Markowitz M, et al. An observational study of rotigotine transdermal patch and other currently prescribed therapies in patients with Parkinson’s disease. J Neural Transm (Vienna). 2018;125(6):953–63.

    Article  CAS  Google Scholar 

  • Müller T, Kuhn W, Möhr JD. Evaluating ADS5102 (amantadine) for the treatment of Parkinson's disease patients with dyskinesia. Expert Opin Pharmacother. 2019;20(10):1181–7.

    Article  PubMed  CAS  Google Scholar 

  • Nutt JG, Carter JH, Lea ES, Woodward WR. Motor fluctuations during continuous levodopa infusions in patients with Parkinson’s disease. Mov Disord. 1997;12(3):285–92.

    Article  CAS  PubMed  Google Scholar 

  • Nutt JG, Chung KA, Holford NH. Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology. 2010;74(15):1191–7.

    Article  PubMed  PubMed Central  Google Scholar 

  • Nyholm D, Nilsson Remahl AI, Dizdar N, Constantinescu R, Holmberg B, Jansson R, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology. 2005;64(2):216–23.

    Article  CAS  PubMed  Google Scholar 

  • Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord. 2006;21(3):343–53.

    Article  PubMed  Google Scholar 

  • Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002;287(13):1653–61.

    Article  Google Scholar 

  • Pearce RK, Heikkila M, Linden IB, Jenner P. L-dopa induces dyskinesia in normal monkeys: behavioural and pharmacokinetic observations. Psychopharmacology. 2001;156(4):402–9.

    Article  CAS  PubMed  Google Scholar 

  • Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2000;68(5):589–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Pirtosek Z. Bad guys’ among the antiparkinsonian drugs. Psychiatr Danub. 2009;21(1):114–8.

    CAS  PubMed  Google Scholar 

  • Pivac N, Pregelj P, Nikolac M, Zupanc T, Nedic G, Muck SD, et al. The association between catechol-O-methyl-transferase Val108/158Met polymorphism and suicide. Genes Brain Behav. 2011;10(5):565–9.

    Article  CAS  PubMed  Google Scholar 

  • Politis M, Wu K, Molloy S, Bain G, Chaudhuri KR, Piccini P. Parkinson’s disease symptoms: the patient’s perspective. Mov Disord. 2010;25(11):1646–51.

    Article  PubMed  Google Scholar 

  • Pourcher E, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012;18(2):178–84.

    Article  PubMed  Google Scholar 

  • Ramot Y, Nyska A, Maronpot RR, Shaltiel-Karyo R, Tsarfati Y, Manno RA, et al. Ninety-day local tolerability and toxicity study of ND0612, a novel formulation of levodopa/carbidopa, administered by subcutaneous continuous infusion in minipigs. Toxicol Pathol. 2017;45(6):764–73.

    Article  CAS  PubMed  Google Scholar 

  • Riederer P, Müller T. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Expert Opin Drug Metab Toxicol. 2017;13(2):233–40.

    Article  CAS  PubMed  Google Scholar 

  • Riederer P, Müller T. Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: clinical-pharmacological aspects. J Neural Transm (Vienna). 2018;125(11):1751–7.

    Article  CAS  Google Scholar 

  • Riederer P, Gerlach M, Müller T, Reichmann H. Relating mode of action to clinical practice: dopaminergic agents in Parkinson’s disease. Parkinsonism Relat Disord. 2007;13(8):466–79.

    Article  PubMed  Google Scholar 

  • Rodnitzky RL, Narayanan NS. Amantadine’s role in the treatment of levodopa-induced dyskinesia. Neurology. 2014;82(4):288–9.

    Article  PubMed  Google Scholar 

  • Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, Papageorgiou K, et al. The impact of COMT gene polymorphisms on suicidality in treatment resistant major depressive disorder – a European multicenter study. Eur Neuropsychopharmacol. 2012;22(4):259–66.

    Article  CAS  PubMed  Google Scholar 

  • Senek M, Nielsen EI, Nyholm D. Levodopa-entacapone-carbidopa intestinal gel in Parkinson’s disease: A randomized crossover study. Mov Disord. 2017;32(2):283–6.

    Article  CAS  PubMed  Google Scholar 

  • Shapira A, Albrecht S, Barone P, Comella C, Hsu H, Massey D, et al. Immediate vs. delayed-start pramipexole in early Parkinson’s disease: the PROUD study. Parkinsonism Relat Disord. 2009;15(2):S81.

    Article  Google Scholar 

  • Singer C. Adverse effects in the treatment of Parkinson’s disease. Expert Rev Neurother. 2002;2(1):105–18.

    Article  PubMed  Google Scholar 

  • Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord. 2003;18(5):487–95.

    Article  PubMed  Google Scholar 

  • Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord. 2008;23(Suppl 3):S599–612.

    Article  PubMed  Google Scholar 

  • Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M. Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75(1):141–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Verhagen ML, Stover N, Chen C, Cowles VE, Sweeney M. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson’s disease. Mov Disord. 2015;30(9):1222–8.

    Article  CAS  Google Scholar 

  • Verschuur CVM, Suwijn SR, Boel JA, Post B, Bloem BR, van Hilten JJ, et al. Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med. 2019;380(4):315–24.

    Article  CAS  PubMed  Google Scholar 

  • Vijverman AC, Fox SH. New treatments for the motor symptoms of Parkinson’s disease. Expert Rev Clin Pharmacol. 2014;7(6):761–77.

    Article  CAS  PubMed  Google Scholar 

  • Wardle MC, Hart AB, Palmer AA, de WH. Does COMT genotype influence the effects of d-amphetamine on executive functioning? Genes Brain Behav. 2013;12(1):13–20.

    Article  CAS  PubMed  Google Scholar 

  • Westin J, Nyholm D, Palhagen S, Willows T, Groth T, Dougherty M, et al. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion. Clin Neuropharmacol. 2011;34(2):61–5.

    CAS  PubMed  Google Scholar 

  • Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, et al. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol. 2003;54(1):93–101.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, St. Joseph Hospital Berlin-Weißensee, Berlin, Germany

    Thomas Müller

Authors
  1. Thomas Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Müller .

Editor information

Editors and Affiliations

  1. Dept Psychiatry , Psychosomatics & Psychotherapy, University of Würzburg, Medical School Clinical Neurochemistry, Würzburg, Germany

    Peter Riederer

  2. Inst für Psychologische Medizin, Haag, Bayern, Germany

    Gerd Laux

  3. Department of Psychiatry, University of Toronto Department of Psychiatry, Toronto, ON, Canada

    Benoit Mulsant

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Fujita Health University School Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

Section Editor information

  1. Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  2. Institute of Environmental Medicine, Nagoya University, Nagoya, Aichi, Japan

    Toshiharu Nagatsu

  3. Department of Physiological Chemistry, Fujita Health University School of Medicine, Toyoake, Aichi, Japan

    Akira Nakashima

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Müller, T. (2020). Clinical Aspects of the Pharmacology and Biochemistry of Drugs for the Treatment of Motor Symptoms of Parkinson’s Disease. In: Riederer, P., Laux, G., Mulsant, B., Le, W., Nagatsu, T. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_215-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-56015-1_215-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-56015-1

  • Online ISBN: 978-3-319-56015-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation